Navigation Links
Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
Date:3/13/2009

PT. RICHMOND, Calif., March 13 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its fourth quarter 2008 on Monday, March 23, 2009, after market close.

A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 23, 2009 and will be hosted by Glenn A. Oclassen, President & Chief Executive Officer, G Kirk Raab, Chairman, Thomas P. Soloway, Senior Vice President & Chief Financial Officer, and Terrence Moore, Vice President, Marketing & Sales.

To participate in the conference call, please dial 877-795-3610 (USA) or 719-325-4764 (International). In addition, a dial-up replay of the conference call will be available beginning March 23, 2009 at 8:00 p.m. ET (5:00 p.m. PT) and ending on April 6, 2009. The replay telephone number is 888-203-1112 (USA) or 719-457-0820 (International), Replay Passcode: 7416010.

A live webcast of the call will also be available from the Investors section on the corporate web site at www.transcept.com. A webcast replay can be accessed on the corporate web site beginning March 23, 2009 at the same time as the conference call and will remain on the site for two weeks ending April 6, 2009.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the Company's website at: www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the ability of merger proceeds to be sufficient to successfully commercialize Intermezzo(R) and the potential for Intermezzo(R) to be the first commercially available sleep aid specifically designed for use in the middle of the night and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, a significant delay in FDA approval of Intermezzo(R); unanticipated additional expenses in connection with the commercialization of Intermezzo(R); Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

    Contacts:

    Transcept Pharmaceuticals, Inc.        The Ruth Group
    Michael Gill                           Investors / Media
    Director of Communications             Stephanie Carrington / Jason Rando
    (510) 215-3575                         (646) 536-7017 / 7025
    mgill@transcept.com                    scarrington@theruthgroup.com
                                           jrando@theruthgroup.com



'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is ... ways to restore a more youthful appearance to the face. Dr. Peyman Ghasri and ... with a variety of other treatments, to rejuvenate and renew the facial appearance. ...
(Date:12/7/2016)... MA (PRWEB) , ... December 07, 2016 , ... They ... They are sisters and wives, brothers and fathers, from New England and around the ... and its stigma, and are brought together in a beautiful and compelling new photographic ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who uses ... why the co-inventor and I have designed a new and better way to secure ... the patent-pending AV-AIR, a device that serves as an alternative to conventional methods of ...
(Date:12/7/2016)... AUSTIN, TX (PRWEB) , ... OCTOBER XX, 2016 ... ... may help solve another mystery. A new study entitled “Canine Filamentous Dermatitis ... Morgellons disease can occur in dogs. The study was published in the prestigious ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to the new market ... by Components (Software, Service), Delivery Modes (Web-based, On-premises, ... Companies, Clinical Research Organization, Medical Device Companies) Global ... 2022", published by Scalar Market Research, the global ... to grow at a healthy CAGR of 14.30% ...
(Date:12/7/2016)... Dec. 7, 2016   TraceLink Inc ., ... connecting the Life Sciences supply chain and eliminating ... announced that Tjoapack has selected TraceLink,s serialization solutions ... comply with the rapidly approaching serialization deadlines for ... in 2017 and the EU Falsified Medicines Directive ...
(Date:12/7/2016)... Dec. 7, 2016  Varian Medical Systems (NYSE: ... previously announced plans to separate its Imaging Components business.  ... tax-free distribution to Varian stockholders of common stock in ... will hold the Imaging Components business.  As part of ... by the end of January 2017, Varian will receive ...
Breaking Medicine Technology: